Clinical Trials on EGFR NP_005219.2:p.S492R

Total 291 results

M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Panitumumab With or Without Trametinib in Treating Patients With Stage IV Colorectal Cancer

EGFR NP_005219.2:p.S492R | KRAS Gene Mutation | MAP2K1 Gene Mutation | Metastatic Colorectal Adenocarcinoma | Refractory Colorectal Adenocarcinoma | Stage IV Colorectal Cancer AJCC v7 | Stage IVA Colorectal Cancer AJCC v7 | Stage IVB Colorectal Cancer AJCC v7

United States
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Completed

Erlotinib Hydrochloride With or Without Bevacizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutations

Lung Non-Squamous Non-Small Cell Carcinoma | Stage IV Lung Non-Small Cell Cancer AJCC v7 | EGFR Exon 19 Deletion Mutation | EGFR NP_005219.2:p.L858R

United States
Blueprint Medicines Corporation

Terminated

(HARMONY) Study of BLU-701 in EGFR-mutant NSCLC

Neoplasms | Respiratory Tract Diseases | Neoplasms by Histologic Type | Lung Diseases | Neoplasms by Site | Adenocarcinoma | Carcinoma | Carcinoma, Non-Small-Cell Lung | Respiratory Tract Neoplasms | Thoracic Neoplasms | Carcinoma, Bronchogenic | Bronchial Neoplasms | Neoplasms, Nerve Tissue | Non Small Cell Lung... and other conditions

United States
Blueprint Medicines Corporation

Active, not recruiting

(SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC

Neoplasms | Neoplasms by Histologic Type | Lung Diseases | Neoplasms by Site | Adenocarcinoma | Carcinoma | Carcinoma, Non-Small-Cell Lung | Lung Neoplasms | Respiratory Tract Neoplasms | Thoracic Neoplasms | Carcinoma, Bronchogenic | Bronchial Neoplasms | Neoplasms, Nerve Tissue | EGF-R Positive Non-Small Cell Lung... and other conditions

United States, Canada, Taiwan, Korea, Republic of, Singapore, Japan, United Kingdom, France, Netherlands, Spain
Centro de Tratamiento e Investigación sobre Cáncer...

Not yet recruiting

Study to Evaluate SBRT for EGFR Mutant NSCLC Patients Receiving Osimertinib (CULTRO) (CULTRO)

Non Small Cell Lung Cancer | EGF-R Positive Non-Small Cell Lung Cancer | EGFR Exon 19 Deletion | EGFR G719X | EGFR Exon 21 Mutation

Colombia
Fujian Cancer Hospital

Unknown

EGFR-TKIs Combine With Anlotinib as First-line Treatment for Patients With Advanced EGFR Mutation-positive NSCLC

EGFR Gene Mutation

China
Shanghai Henlius Biotech

Not yet recruiting

A Randomized, Single Intravenous Dose, Parallel Phase I Clinical Study to Compare the Pharmacokinetic Characteristics, Safety, and Immunogenicity of HLX05 Vs. Erbitux® (Cetuximab) in Healthy Adult Male Chinese Subjects

EGFR Overexpression
Fujian Cancer Hospital

Unknown

EGFR-TKIs Combine Chemotherapy as First-line Therapy for Patients With Advanced EGFR Mutation-positive NSCLC (effect)

EGFR Gene Mutation
Tianjin Medical University Second Hospital

Recruiting

Nimotuzumab for EGFR-amplified Advanced Pan Solid Tumors

Solid Tumor | EGFR Amplification

China
Shanghai Henlius Biotech

Not yet recruiting

A Study to Evaluate the Efficacy and Safety of HLX07 in nsqNSCLC Patients With High EGFR Expression

HLX07, nsqNSCLC, High EGFR Expression

China
Chinese PLA General Hospital

Recruiting

TGFβR-KO CAR-EGFR T Cells in Previously Treated Advanced EGFR-positive Solid Tumors

Solid Tumor, Adult | EGFR Overexpression

China
Chinese PLA General Hospital

Unknown

Treatment of Chemotherapy Refractory EGFR(Epidermal Growth Factor Receptor) Positive Advanced Solid Tumors (CART-EGFR) (CART-EGFR)

Advanced EGFR-positive Solid Tumors

China
AstraZeneca

Completed

ARTEMIS DIANE T790M (An Amino Acid Substitution at Position 790 in EGFR, From a Threonine (T) to a Methionine (M)) Mutation at Hospital Laboratories in Comparison With Central Laboratory

Locally Advanced or Metastatic EGFR(+) NSCLC Patients

China
AstraZeneca

Completed

A Retrospective, Non-interventional, Multicenter, Observational Chart Review Study to Explore the Clinical Benefits of Retreatment With TKI in the Real World. (SEQUENCE)

Locally Advanced or Metastatic EGFR Mutated NSCLC.

Taiwan
ImmunoGen, Inc.

Terminated

A Phase 1 Study of IMGN289 in Adult Patients With EGFR-positive Solid Tumors

EGFR Positive Solid Tumors

United States
Changchun Intellicrown Pharmaceutical Co. LTD
Covance

Recruiting

ZZ06 in Adult Patients With Advanced EGFR Positive Solid Tumor Malignancies

Advanced EGFR Positive Solid Tumor

United States, China
Sun Yat-sen University

Recruiting

A Study of Gefitinib With or Without Apatinib in Patients With Advanced Non-squamous Non-Small-Cell Lung Cancer Harboring EGFR Mutations

EGFR Tyrosine Kinase Inhibitors Plus VEGFR Inhibitors

China
Bristol-Myers Squibb

Completed

MAD Refractory: Solid Tumor QD w/o Break

HER2 or EGFR Expressing Advanced Solid Malignancies

Spain, France
AstraZeneca

Completed

Asia Pacific and Russia Diagnostic Study for EGFR Testing (IGNITE)

EGFR Mutation Status in aNSCLC Patients

Korea, Republic of, Russian Federation, Malaysia, China, Australia, Taiwan, Thailand, Indonesia, Singapore
Astellas Pharma Global Development, Inc.

Withdrawn

A Study to Investigate the Absorption, Metabolism and Excretion of [14C]ASP8273 in Subjects With Solid Tumors

Solid Tumors | Epidermal Growth Factor Receptor (EGFR) Mutations
Chongqing University Cancer Hospital
Army Specialty Medical Center; The Second Affilicated Hospital of Chongqing...

Recruiting

First-line Furmonertinib in Advanced NSCLC Patients With EGFR Uncommon Mutation

Non-small Cell Lung Cancer | EGFR G719X | EGFR L861Q | EGFR S768I

China
Intergroupe Francophone de Cancerologie Thoracique

Recruiting

A Prospective Cohort Study to Evaluate Molecular pRognostic Factors and Resistance Mechanisms to Osimertinib in Adjuvant Treatment of Completely Resected pIB-IIIA Non-small Cell Lung Carcinoma With Common EGFR Mutations (L858R and Del19) (ROSIE)

Non Small Cell Lung Cancer | EGFR Activating Mutation | EGFR L858R | EGFR DEL19

France
The First Affiliated Hospital of Guangzhou Medical...

Unknown

Erlotinib 100mg or 150mg in Treating EGFR Mutated NSCLC

NSCLC | EGFR Mutation

China
Fujian Cancer Hospital

Not yet recruiting

Almonertinib Plus Metronomic Oral Vinorelbine

NSCLC | EGFR | Third-generation TKI
Nalo Therapeutics Inc.

Recruiting

A Study of NX-019 in Patients With Advanced, Epidermal Growth Factor Receptor (EGFR) Mutant Cancer

EGFR Mutation-Related Tumors

Korea, Republic of, United States, Taiwan
Shenzhen People's Hospital

Unknown

To Evaluate the Efficacy and Safety of Gefitinib in Adjuvant Chemotherapy for Lung Adenocarcinoma (RCTACSCNSCLC)

NSCLC | EGFR

China
Blueprint Medicines Corporation

Active, not recruiting

(Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations

Neoplasms | Neoplasms by Histologic Type | Lung Diseases | Neoplasms by Site | Adenocarcinoma | Carcinoma | Carcinoma, Non-Small-Cell Lung | Respiratory Tract Neoplasms | Carcinoma, Bronchogenic | Bronchial Neoplasms | Metastatic Lung Cancer | Antineoplastic Agents | Brain Metastases | Lung Neoplasm Malignant | EGFR... and other conditions

United States, Canada, Korea, Republic of, Japan, Taiwan
Incyte Corporation

Terminated

Efficacy and Safety of Pemigatinib in Participants With Solid Tumors With FGFR Mutations or Translocations (FIGHT-208)

Advanced or Metastatic Solid Tumors | FGFR Mutations | FGFR Translocations

United States
Shenzhen People's Hospital

Unknown

Apatinib Combined With EGFR-TKI for Advanced Slow-progressed EGFR-TKI Resistant NSCLC (AFLC)

NSCLC | Apatinib | EGFR-TKI

China
AstraZeneca

No longer available

AZD9291 US Expanded Access Program

EGFR T790M Mutation Positive NSCLC

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation

Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | KRAS Gene Mutation | Metastatic Malignant Solid Neoplasm | EGFR Gene Mutation | ERBB2 Gene Amplification | ERBB2 Gene Mutation | EGFR Gene Amplification | ERBB3 Gene Mutation | ERBB4 Gene Mutation

United States
Tianjin Medical University Cancer Institute and...

Not yet recruiting

Safety and Efficacy of Aumolertinib Combined With Anlotinib as 1st Line Treatment in Advanced Lung Cancer EGFR Mutation With TP53 Co-Mutation

NSCLC | EGFR Activating Mutation | Anlotinib | TP53 | Aumolertinib
ETOP IBCSG Partners Foundation
AstraZeneca

Active, not recruiting

Osimertinib and Locally Ablative Radiotherapy in Patients With Synchronous Oligo-metastatic EGFR Mutant NSCLC (STEREO) (STEREO)

NSCLC Stage IV | EGFR Gene Mutation

Singapore, Sweden, Korea, Republic of, Spain, Switzerland, Netherlands, Italy, Poland
Spectrum Pharmaceuticals, Inc

Completed

Safety, Tolerability and Systemic Absorption of Menadione Topical Lotion for Epidermal-Growth-Factor-Receptor (EGFR) Inhibitor-Associated Rash

EGFR Inhibitor-associated Rash

United States, Canada
TWi Biotechnology, Inc.

Completed

Prophylactic Treatment of Skin Rash Associated With EGFR Inhibitor Therapy

EGFR Inhibitor-Induced Skin Rash

Taiwan
Chinese University of Hong Kong
Pamela Youde Nethersole Eastern Hospital

Completed

ATOM_local Ablative Therapy

NSCLC | Activating EGFR Mutation

Hong Kong
AstraZeneca

Completed

Efficacy, Safety, Tolerability of Gefitinib as 1st Line in Caucasian Patients With EGFR Mutation Positive Advanced NSCLC (IFUM)

Caucasian Patients With EGFR Mutation Positive Advanced NSCLC

Bulgaria, Italy, Poland, Spain, Turkey, United Kingdom, Romania, Norway, Hungary, Portugal, Greece, Switzerland, France
Hellenic Cooperative Oncology Group

Completed

The Molecular Epidemiology of Epidermal Growth Factor Receptor (EGFR) Mutations in Patients With Advanced EGFR Mutation-positive Non-small Cell Lung Cancer Treated With Afatinib

Non Small Cell Lung Cancer | EGF-R Positive Non-Small Cell Lung Cancer | EGFR Gene Mutation
AstraZeneca

Completed

Study of AZD9291 Plus MEDI4736 Versus AZD9291 Monotherapy in NSCLC After Previous EGFR TKI Therapy in T790M Mutation Positive Tumours (CAURAL)

Locally Advanced or Metastatic EGFR T790M+ NSCLC

Canada, Korea, Republic of, Taiwan
Yuhan Corporation

Active, not recruiting

Clinical Trial of YH25448 in Patients With EGFR Mutation Positive Advanced NSCLC

EGFR Gene Mutation

Korea, Republic of
Sierra Oncology, Inc.

Terminated

Erlotinib and Momelotinib for the Treatment of Epidermal Growth Factor Receptor (EGFR) Mutated EGFR Tyrosine Kinase Inhibitor (TKI) Naive Metastatic Non-Small Cell Lung Cancer (NSCLC)

EGFR Mutated EGFR TKI Naive Metastatic NSCLC

United States
University of Virginia

Active, not recruiting

Real-Time Monitoring of Symptoms in Lung Cancer Patients Receiving Oral Targeted Therapies (Lung001)

Lung Cancer | ALK Gene Mutation | MET Gene Mutation | KRAS Mutation-Related Tumors | RET Gene Mutation | EGFR Gene Mutation | EGFR | ROS1 Gene Mutation | BRAF

United States
Shanghai Chest Hospital
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Not yet recruiting

Almonertinib Treats Advanced NSCLC Patients With EGFR Mutations Who Are Safety Intolerant After Osimertinib Treatment (ACTIVE)

Lung Cancer | EGFR Gene Mutation
Astellas Pharma Global Development, Inc.

Withdrawn

A Study for Subjects Who Are Participating in an Astellas-sponsored ASP8273 Study

Subjects With NSCLC With an EGFR Activating Mutation
Jonsson Comprehensive Cancer Center
AstraZeneca

Active, not recruiting

18F-FDG PET and Osimertinib in Evaluating Glucose Utilization in Patients With EGFR Activated Recurrent Glioblastoma

Glioblastoma | Recurrent Glioblastoma | EGFR Gene Mutation | Supratentorial Glioblastoma | EGFR Gene Amplification | TP53 wt Allele

United States
GenoSaber
Sun Yat-sen University; Shanghai Chest Hospital; Shanghai Pulmonary Hospital,...

Unknown

Human EGFR Mutations Quantitative Detection Kit (Real-time Fluorescent PCR Method)

Non Small Cell Lung Cancer | EGFR-TKI Resistant Mutation | EGFR-TKI Sensitizing Mutation
Astellas Pharma Inc

Terminated

A Study of ASP8273 in Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor-Naïve Patients With Non-Small Cell Lung Cancer Harboring EGFR Mutations

EGFR-TKI-naïve Patients With NSCLC Harboring EGFR Activating Mutations

Japan
Puma Biotechnology, Inc.

Terminated

Basket Study of Neratinib in Participants With Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations (SUMMIT)

Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations

France, United States, Spain, Belgium, United Kingdom, Serbia, Australia, Israel, Canada, Denmark, Ireland, Italy, Korea, Republic of
Henan Cancer Hospital

Unknown

S-1 Plus Gefitinib Versus Gefitinib Monotherapy in Patients With EGFR-sensitive Mutation Advanced Non-squamous NSCLC

Advanced NSCLC With EGFR Mutation

China
Massachusetts General Hospital

Not yet recruiting

Long-term Follow-up of Subjects Treated With CARv3-TEAM-E T Cells

Glioblastoma Recurrent, EGFR vIII Mutant | Newly Diagnosed Glioblastoma, EGFRvIII Mutant | Recurrent Glioblastoma, EGFR vIII Negative

United States

Clinical Trials on EGFR NP_005219.2:p.S492R

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ecuador

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations